Literature DB >> 26791379

Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.

Wataru Yamamoto1,2, Eriko Fujii3, Kenji Matsumoto3,4, Eri Yamamoto3, Jun Aoki3, Masatsugu Tanaka3, Yoshiaki Ishigatsubo5, Heiwa Kanamori3.   

Abstract

The impact of pre-transplant serum C-reactive protein (CRP) level on the outcome of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC allo-SCT) is unclear. This study retrospectively investigated 78 patients who underwent RIC allo-SCT between 2005 and 2013. The conditioning regimen consisted of fludarabine and melphalan with/without total body irradiation. The 3-year overall survival of high CRP (43.6 % of all patients) patients was significantly worse than that of normal CRP patients in whom CRP was ≤0.3 mg/dl (26.7 vs. 74.1 %, P < 0.001). Both the CRP level before transplantation and disease risk status were independent prognostic factors for overall survival by multivariate analysis. CRP was not a significant predictor of NRM by multivariate analysis (hazard ratio 3.2, 95 % confidence interval 0.8-13.1, P = 0.100). These results suggest that measuring the CRP level before transplantation can be useful to predicting the outcome of RIC allo-SCT.

Entities:  

Keywords:  Allogeneic stem cell transplantation; Reduced-intensity conditioning; Serum C-reactive protein

Mesh:

Substances:

Year:  2016        PMID: 26791379     DOI: 10.1007/s12185-016-1941-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

1.  IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease.

Authors:  Lidia Karabon; Barbara Wysoczanska; Katarzyna Bogunia-Kubik; Krzysztof Suchnicki; Andrzej Lange
Journal:  Hum Immunol       Date:  2005-03-19       Impact factor: 2.850

2.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

3.  Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation.

Authors:  J Kanda; C Mizumoto; T Ichinohe; H Kawabata; T Saito; K Yamashita; T Kondo; S Takakura; S Ichiyama; T Uchiyama; T Ishikawa
Journal:  Bone Marrow Transplant       Date:  2010-05-03       Impact factor: 5.483

4.  C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation.

Authors:  Mats Remberger; Jonas Mattsson
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

5.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

Authors:  Paul M Ridker; Nader Rifai; Lynda Rose; Julie E Buring; Nancy R Cook
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

6.  Pretransplant C-reactive protein as A prognostic marker in allogeneic stem cell transplantation.

Authors:  K K I Jordan; I J Christensen; C Heilmann; H Sengeløv; K G Müller
Journal:  Scand J Immunol       Date:  2014-03       Impact factor: 3.487

7.  Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Soichiro Sakamoto; Hiroshi Kawabata; Junya Kanda; Tatsuki Uchiyama; Chisaki Mizumoto; Tadakazu Kondo; Kouhei Yamashita; Tatsuo Ichinohe; Takayuki Ishikawa; Norimitsu Kadowaki; Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2012-12-07       Impact factor: 2.490

8.  Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation.

Authors:  Şahika Zeynep Akı; Elif Suyanı; Yelda Bildacı; Merih Kızıl Çakar; Nuran Ahu Baysal; Gülsan Türköz Sucak
Journal:  Clin Transplant       Date:  2012 Sep-Oct       Impact factor: 2.863

9.  A risk score for mortality after allogeneic hematopoietic cell transplantation.

Authors:  Tanyalak Parimon; David H Au; Paul J Martin; Jason W Chien
Journal:  Ann Intern Med       Date:  2006-03-21       Impact factor: 25.391

10.  Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.

Authors:  Andrew S Artz; Amittha Wickrema; Shira Dinner; Lucy A Godley; Masha Kocherginsky; Olatoyosi Odenike; Elizabeth S Rich; Wendy Stock; Jodie Ulaszek; Richard A Larson; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

View more
  3 in total

1.  Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation.

Authors:  Maria Queralt Salas; Eshetu G Atenafu; Ora Bascom; Leeann Wilson; Wilson Lam; Arjun Datt Law; Ivan Pasic; Dennis Dong Hwan Kim; Fotios V Michelis; Zeyad Al-Shaibani; Armin Gerbitz; Auro Viswabandya; Jeffrey Howard Lipton; Jonas Mattsson; Shabbir M H Alibhai; Rajat Kumar
Journal:  Bone Marrow Transplant       Date:  2020-06-30       Impact factor: 5.483

2.  Prediction of clinical outcome by controlling nutritional status (CONUT) before allogeneic hematopoietic stem cell transplantation in myeloid malignancies.

Authors:  Hiroaki Araie; Yuka Kawaguchi; Motohito Okabe; Yoonha Lee; Marie Ohbiki; Masahide Osaki; Miyo Goto; Tatsunori Goto; Takanobu Morishita; Yukiyasu Ozawa; Koichi Miyamura
Journal:  Int J Hematol       Date:  2019-08-12       Impact factor: 2.490

3.  Clinical profile, biological markers, and comorbidity index as predictors of transplant-related mortality after allo-HSCT.

Authors:  Aliénor Xhaard; Renato Cunha; Marc Busson; Marie Robin; Nathalie Dhedin; Tereza Coman; Aurélie Cabannes-Hamy; Flore Sicre de Fontbrune; David Michonneau; Gérard Socié; Rodrigo T Calado; Régis Peffault de Latour
Journal:  Blood Adv       Date:  2017-08-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.